More News

New target for cancer treatment

Jim Cornall -
Scientists have uncovered an unexpected way cells can generate cancer-driving proteins—by cutting RNA into shorter, functional fragments rather than...

Researchers identify key protein in inflammatory response to infections

Jim Cornall -
Whenever there is a wound or infection, the body produces an inflammatory response. This is the body’s first line...

Experimental drug protects body from harmful effects of gluten

Jim Cornall -
An experimental drug may provide a new form of protection for people with coeliac disease. According to an international...

Japanese pharma companies shifting to earlier CDMO outsourcing

Jim Cornall -
Japanese pharmaceutical companies are engaging contract development and manufacturing organisations (CDMOs) earlier in the development cycle, as increasing complexity...

Promising cell model for dementia research

Jim Cornall -
Researchers at LMU have developed a human cell model that replicates key mechanisms of neurodegenerative diseases – with potential...

Antibodies offer hope for autoimmune diseases

Jim Cornall -
The immune system is our frontline protection against infection, continually searching for and destroying unknown pathogens. While operation of...

New lung cancer model reveals tumour location shapes the immune response

Jim Cornall -
Researchers at VIB and VUB have developed a powerful new way to study how the immune system behaves inside...

ADHD-related traits may intensify chronic pain

Jim Cornall -
Chronic pain evades common treatments and affects millions of people around the world. Pain is not a purely physical...

Hidden mechanism in DNA damage

Jim Cornall -
For decades, researchers have studied how oxidative stress affects DNA and have found that guanine, one of its four...

Base to Base biotech podcast 56: GRIN genes and relapsing MS

Jim Cornall -
This week, our conversations are with Bruce Leuchter, co-founder, president, CEO of Neurvati Neurosciences and GRIN Therapeutics; and Daniel...

Positive first-in-human data for IVF-related embryo implantation failure treatment

Jim Cornall -
Freya Biosciences has announced positive topline results from its phase 1 first-in-human clinical study evaluating FB301, a defined multi-strain...

New company plans to replace daily injections with implant

Jim Cornall -
RBL LLC has launched Duracyte, a biotechnology company commercialising a pioneering class of implantable "biohybrid pharmacy" devices designed to...

UCB adds epilepsy drug through Neurona Therapeutics acquisition

Jim Cornall -
UCB has entered into a definitive agreement under which UCB would acquire Neurona Therapeutics, including lead asset NRTX-1001, adding...

Mechanism ‘opens new era’ for targeted cancer therapy

Jim Cornall -
Penetrium Bioscience has announced new scientific evidence demonstrating, for the first time at the cellular level, the underlying mechanism...

myTomorrows and Rare Disease Research partner to improve access to rare disease clinical trials

Jim Cornall -
myTomorrows, a health technology company that helps connect patients and physicians to pre-approval treatment options, and Rare Disease Research...

Resolve Therapeutics and Institut Pasteur collaborate to identify cell-free RNA triggers in autoimmunity

Jim Cornall -
Resolve Therapeutics and the Institut Pasteur de Montevideo in Uruguay will collaborate to identify the central upstream triggers that...

Stem cell therapy for type 1 diabetes

Jim Cornall -
Researchers at Karolinska Institutet and KTH Royal Institute of Technology in Sweden have developed an improved method for creating...

New technique maps cancer drug uptake inside living cells

Jim Cornall -
A new analytical method could improve how cancer treatments are designed – by allowing scientists to track, for the...

Group develops inhaled therapy to reduce lung damage from severe infections

Jim Cornall -
Nanyang Technological University, Singapore (NTU Singapore) is working with China’s Southern University of Science and Technology (SUSTech) and Swedish...

Circio enters in vivo cell therapy evaluation agreement with Acuitas Therapeutics

Jim Cornall -
Circio Holding ASA has initiated a technology evaluation agreement in the area of in vivo CAR-T cell therapy with...

CRISPR variant selectively targets tumour DNA

Jim Cornall -
Cancer cells excel at evading detection, but subtle chemical differences set them apart from healthy cells. Wageningen University &...